Abstract: The present disclosure provides compositions and therapies that can address both the symptoms and disorders associated with insufficient surfactant production and hyperoxia. In one embodiment, the composition can be formulated for aerosol delivery during ventilation therapy. The composition can comprise one or more of the following: a PPAR gamma agonist, a surfactant peptide, and one or more phospholipids. The compositions are formulated to provide the complementary benefits of reducing the likelihood of developing or the severity of RDS in infants, as well as protecting and promoting lung maturation in a hyperoxic environment.
Type:
Grant
Filed:
March 6, 2017
Date of Patent:
November 23, 2021
Assignee:
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR—UCLA MEDICAL CENTER
Inventors:
Virender K. Rehan, John S. Torday, Frans J. Walther, Alan J. Waring, Larry M. Gordon